The Patent Finder

Orphai Therapeutics Inc.

18 patents currently held · Updated Nov 18, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 2 name spellings.

Previously recorded as AI Therapeutics, Inc. (to 2023)

1
Ending by 2030
Nov 2030
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Mar 5, 2027
    The maintenance fee for Rapamycin for the Treatment of Lymphangioleiomyomatosis (US 11,744,797) comes due Mar 5, 2027. Unpaid by Sep 7, 2027, it lapses early.
  • 1 fee due Aug 25, 2027
    The maintenance fee for Combinations of a Mithramycin Analogue and Another Chemotherapeutic Agent for the Treatment of Triple Negative Breast Cancer (US 10,568,899) comes due Aug 25, 2027. Unpaid by Feb 25, 2028, it lapses early.
  • 1 fee due Oct 16, 2027
    The maintenance fee for Combination Therapy with Apilimod and Glutamatergic Agents (US 11,957,688) comes due Oct 16, 2027. Unpaid by Apr 17, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 8,772,253Aureolic Acid Derivatives, the Method for Preparation Thereof and the Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 10,307,370Rapamycin for the Treatment of Lymphangioleiomyomatosis
In force
 · High confidence
In forceHigh confidence
US 10,307,371Rapamycin for the Treatment of Lymphangioleiomyomatosis
In force
 · Low confidence
In forceLow confidence
US 11,123,289Rapamycin for the Treatment of Lymphangioleiomyomatosis
In force
 · Medium confidence
In forceMedium confidence
US 12,171,874Rapamycin for the Treatment of Lymphangioleiomyomatosis
In force
 · Low confidence
In forceLow confidence
US 11,744,797Rapamycin for the Treatment of Lymphangioleiomyomatosis
In force
 · Low confidence
In forceLow confidence
US 10,179,135Apilimod Compositions and Methods for Using Same
In force
 · High confidence
In forceHigh confidence
US 11,103,449An Inhalable Rapamycin Formulation for Treating Age-Related Conditions
In force
 · High confidence
In forceHigh confidence
US 11,648,199Inhalable Rapamycin Formulation for Treating Age-Related Conditions
In force
 · Medium confidence
In forceMedium confidence
US 11,491,143Inhalable Rapamycin Formulation for the Treatment of Pulmonary Hypertension
In force
 · Medium confidence
In forceMedium confidence
10 of 18 patents shown.
Pro members see all 18.
Pro members: see all 18 patents
Also on record, not counted in the 18: 5 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

3 pending

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited